RSV Economic Modelling

Infection with Respiratory Syncytial Virus (RSV) can result in serious illness and hospitalization for infants and older adults, creating a high health and financial burden in Canada.

We developed a dynamic transmission model for RSV that is specific to Canadian data, along with an economic component to model disease outcomes alongside disease and intervention costs. The ultimate goal was to provide the National Advisory Committee on Immunizations (NACI) with a model to test the cost-effectiveness of future RSV vaccines licensed in Canada.

Project dates

June 1, 2019 to March 31, 2022


  • Public Health Agency of Canada
  • Alberta Health
  • Canadian Institutes of Health Research

Browse all projects

If this was not quite what you were looking for, or you just want to learn more about our immunization research, explore the wealth of other projects we’ve done.